

# Bassam Janji

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7067398/publications.pdf>

Version: 2024-02-01

72  
papers

14,503  
citations

81900

39  
h-index

110387

64  
g-index

73  
all docs

73  
docs citations

73  
times ranked

28965  
citing authors

#	ARTICLE	IF	CITATIONS
1	Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1392.	3.7	16
2	Nanoluciferase-based methods to monitor activation, modulation and trafficking of atypical chemokine receptors. <i>Methods in Cell Biology</i> , 2022, , 279-294.	1.1	9
3	Mitochondria preserve an autarkic one-carbon cycle to confer growth-independent cancer cell migration and metastasis. <i>Nature Communications</i> , 2022, 13, 2699.	12.8	20
4	CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT. <i>Journal of Cellular Biochemistry</i> , 2022, , .	2.6	3
5	The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
6	“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy. <i>Onc Immunology</i> , 2021, 10, 1968611.	4.6	4
7	Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 626309.	2.8	22
8	Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer. <i>Cancers</i> , 2021, 13, 1165.	3.7	24
9	CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6. <i>Cancers</i> , 2021, 13, 1054.	3.7	25
10	Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy. <i>Oncogene</i> , 2021, 40, 4725-4735.	5.9	70
11	Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR (ezrin) pathway. <i>Autophagy</i> , 2020, 16, 1436-1452.	9.1	114
12	The emerging impact of autophagy on the antitumor immune response. , 2020, , 109-117.		0
13	Firing up the cold tumors by targeting Vps34. <i>Onc Immunology</i> , 2020, 9, 1809936.	4.6	24
14	Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34. <i>Autophagy</i> , 2020, 16, 2110-2111.	9.1	25
15	Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy. <i>Science Advances</i> , 2020, 6, eaax7881.	10.3	164
16	Assessing Autophagy in Archived Tissue or How to Capture Autophagic Flux from a Tissue Snapshot. <i>Biology</i> , 2020, 9, 59.	2.8	12
17	Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. <i>Cells</i> , 2019, 8, 1083.	4.1	153
18	Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. <i>Cancer Letters</i> , 2019, 458, 13-20.	7.2	83

#	ARTICLE	IF	CITATIONS
19	The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. <i>Cells</i> , 2019, 8, 613.	4.1	60
20	Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. <i>Blood</i> , 2018, 131, 1617-1621.	1.4	101
21	Targeting autophagy blocks melanoma growth by bringing natural killer cells to the tumor battlefield. <i>Autophagy</i> , 2018, 14, 730-732.	9.1	34
22	Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target. <i>Oncolmmunology</i> , 2018, 7, e1452583.	4.6	18
23	CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT. <i>Oncolmmunology</i> , 2018, 7, e1345415.	4.6	63
24	Hypoxia promotes breast cancer cell invasion through HIF-1 $\alpha$ -mediated up-regulation of the invadopodial actin bundling protein CSRP2. <i>Scientific Reports</i> , 2018, 8, 10191.	3.3	59
25	Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 887.	4.8	63
26	High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia. <i>Oncolmmunology</i> , 2018, 7, e1465167.	4.6	15
27	Inhibition of HIF1 $\alpha$ -Dependent Upregulation of Phospho-F-Actin Resensitizes Multiple Myeloma Cells to Frontline Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1551.	4.1	9
28	Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity. <i>Cancer Research</i> , 2018, 78, 5631-5643.	0.9	93
29	Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the Shots. <i>Critical Reviews in Oncogenesis</i> , 2018, 23, 321-332.	0.4	5
30	Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L Promoter. <i>Journal of Immunology</i> , 2017, 198, 1423-1428.	0.8	36
31	The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. <i>Oncolmmunology</i> , 2017, 6, e1263412.	4.6	193
32	Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9271-E9279.	7.1	181
33	Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A. <i>British Journal of Cancer</i> , 2017, 117, 813-825.	6.4	89
34	Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. <i>Oncotarget</i> , 2017, 8, 24031-24044.	1.8	77
35	Autophagy Activation in the Tumor Microenvironment. , 2016, , 267-290.		0
36	The multifaceted role of autophagy in tumor evasion from immune surveillance. <i>Oncotarget</i> , 2016, 7, 17591-17607.	1.8	53

#	ARTICLE	IF	CITATIONS
37	Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet. <i>Frontiers in Oncology</i> , 2016, 6, 246.	2.8	22
38	Role of Autophagy in Tumor Progression and Regression. <i>Current Cancer Research</i> , 2016, , 117-131.	0.2	0
39	Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF- $\beta$ 2 and miR23a transfer. <i>OncoImmunology</i> , 2016, 5, e1062968.	4.6	247
40	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
41	Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. <i>European Urology</i> , 2016, 70, 623-632.	1.9	115
42	miR-210 and hypoxic microvesicles: Two critical components of hypoxia involved in the regulation of killer cells function. <i>Cancer Letters</i> , 2016, 380, 257-262.	7.2	33
43	CRP2, a new invadopodia actin bundling factor critically promotes breast cancer cell invasion and metastasis. <i>Oncotarget</i> , 2016, 7, 13688-13705.	1.8	33
44	Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. <i>Blood</i> , 2015, 126, 1106-1117.	1.4	399
45	Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells. <i>PLoS ONE</i> , 2015, 10, e0130339.	2.5	11
46	Autophagy Regulation of the Tumor Immunity – An Old Machinery for a New Function. , 2015, , .		0
47	The autophagy sensor ITPR1 protects renal carcinoma cells from NK-mediated killing. <i>Autophagy</i> , 2015, , 00-00.	9.1	32
48	Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 309, C569-C579.	4.6	316
49	The Selective Degradation of Synaptic Connexin 43 Protein by Hypoxia-induced Autophagy Impairs Natural Killer Cell-mediated Tumor Cell Killing. <i>Journal of Biological Chemistry</i> , 2015, 290, 23670-23679.	3.4	81
50	Emerging Role of Hypoxia-Induced Autophagy in Cancer Immunotherapy. , 2014, , 247-262.		1
51	Tumor Plasticity Interferes with Anti-Tumor Immunity. <i>Critical Reviews in Immunology</i> , 2014, 34, 91-102.	0.5	44
52	Autophagic degradation of GZMB/granzyme B. <i>Autophagy</i> , 2014, 10, 173-175.	9.1	73
53	ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy. <i>Cancer Research</i> , 2014, 74, 6820-6832.	0.9	97
54	PD-L1 is a novel direct target of HIF-1 $\alpha$ , and its blockade under hypoxia enhanced MDSC-mediated T cell activation. <i>Journal of Experimental Medicine</i> , 2014, 211, 781-790.	8.5	1,601

#	ARTICLE	IF	CITATIONS
55	Autophagy: An adaptive metabolic response to stress shaping the antitumor immunity. <i>Biochemical Pharmacology</i> , 2014, 92, 31-42.	4.4	76
56	Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell-Mediated Lysis. <i>Cancer Research</i> , 2013, 73, 2418-2427.	0.9	255
57	EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction. <i>Autophagy</i> , 2013, 9, 1104-1106.	9.1	69
58	The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2013, 4, 490.	4.8	155
59	Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17450-17455.	7.1	263
60	Hypoxia-induced autophagy. <i>Autophagy</i> , 2012, 8, 704-706.	9.1	56
61	Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells. <i>Cancer Research</i> , 2012, 72, 4629-4641.	0.9	168
62	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
63	Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression. <i>Cancer Research</i> , 2011, 71, 5976-5986.	0.9	223
64	Microenvironmental Hypoxia Orchestrating the Cell Stroma Cross Talk, Tumor Progression and Antitumor Response. <i>Critical Reviews in Immunology</i> , 2011, 31, 357-377.	0.5	83
65	The acquisition of resistance to TNF $\alpha$ in breast cancer cells is associated with constitutive activation of autophagy as revealed by a transcriptome analysis using a custom microarray. <i>Autophagy</i> , 2011, 7, 760-770.	9.1	99
66	The actin filament cross-linker L-plastin confers resistance to TNF $\alpha$ in MCF7 breast cancer cells in a phosphorylation-dependent manner. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 1264-1275.	3.6	34
67	The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1349-1360.	4.1	42
68	Peroxisome proliferator-activated receptor $\beta$ agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells. <i>British Journal of Haematology</i> , 2009, 147, 662-671.	2.5	19
69	Phosphorylation on Ser5 increases the F-actin-binding activity of L-plastin and promotes its targeting to sites of actin assembly in cells. <i>Journal of Cell Science</i> , 2006, 119, 1947-1960.	2.0	93
70	Role of Autophagy in Cancer and Tumor Progression. , 0, , .		11
71	The Critical Role of Hypoxia in Tumor-Mediated Immunosuppression. , 0, , .		1
72	The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4